Search

for
Search:

Learn

0 / 0 results

— no results

Research

5 / 38 results

A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia

research A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia

August 2025 in “Cureus”

The 0.05% dutasteride topical solution effectively promotes hair growth with fewer side effects than oral treatments.

A Randomized, Single-Blind Trial of 5% Minoxidil Foam Once Daily Versus 2% Minoxidil Solution Twice Daily in the Treatment of Androgenetic Alopecia in Women

research A Randomized, Single-Blind Trial of 5% Minoxidil Foam Once Daily Versus 2% Minoxidil Solution Twice Daily in the Treatment of Androgenetic Alopecia in Women

100 citations , June 2011 in “Journal of The American Academy of Dermatology”

5% minoxidil foam once daily works as well as 2% minoxidil solution twice daily for female hair growth and is more convenient.

research Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

January 2025

Topical GT20029 effectively promotes hair regrowth and is well-tolerated.

Efficacy and Safety of Topical KX-826 in Male Subjects with Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study

research Efficacy and Safety of Topical KX-826 in Male Subjects with Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study

November 2022 in “Journal of Investigative Dermatology”

KX-826 is safe and effectively increases hair count in men with hair loss.

research Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

January 2025

Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.

View more "tahc improvement" in research →

Community Join

5 / 40 results

community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide

in Update 50 upvotes 2 years ago

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

community Why do I have the feeling that this subreddit is flooded by Kintor employees?

in Chat 132 upvotes 1 year ago

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

community To everyone who cant use FIN and doesnt want to use RU

in Treatment 33 upvotes 1 year ago

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

community KX-826+Minoxidil Outperforms Minoxidil Alone for AGA Treatment: 30+ New Hairs/cm² (24 Weeks, P=0.0075)

in Research/Science 41 upvotes 5 months ago

KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.

community Solution for male pattern baldness

in Treatment 242 upvotes 2 weeks ago

A new hair loss treatment claims a 539% improvement over placebo, but skepticism remains due to lack of substantial evidence and reliance on percentage figures. Users discuss the effectiveness of existing treatments like Minoxidil and Finasteride, expressing doubt about the new solution's impact.

View more "tahc improvement" in community →